Environmental Health Sciences Bridging the Gap between Exposure, Mechanism and Public Health Seminar
Event Mark H. Mirkin
Rimon Partner Mark Mirkin will be speaking at The Environmental Mutagenesis & Genomics Society’s 48th Annual Meeting: Environmental Health Sciences Bridging the Gap between Exposure, Mechanism and Public Health.
Mr. Mirkin will present at a workshop titled Entrepreneurship, Economic Initiatives and Bioscience Incubators. His discussion of the business perspective of how to start a life science company will focus on the most common issues like identifying business leadership, dealing with investors, developing a business plan, or finding the right role.
This topic will be of interest to entrepreneurs and to academicians interested in learning how to commercialize their inventions.
Date: September 09, 2017, Saturday
Time: 12 pm to 3 pm
Location: Raleigh Convention Center, Raleigh, NC
The EMGS Annual Meeting uniquely brings together leading scientists from academia, industry, and government to discuss cutting-edge research aimed at understanding and mitigating environmental threats to the genome and to the epigenome.
By forging a bridge to bring scientists studying exposures, mechanisms, and regulatory sciences, the 2017 Annual Meeting of the Environmental Mutagenesis and Genomics Society (EMGS) will provide a venue for stimulating cross-disciplinary research and discovery. Aspects like how environmental agents impact genomic, proteomic and metabolic signatures, and how this knowledge base can be used to develop informed biomarkers and improved regulatory policies that address human health concerns related to environmental exposures will be covered.
About the presenter: Mark Mirkin focuses his practice on strategic corporate and securities counseling to emerging and high-growth companies, especially in the context of seed, early stage and venture capital financings, mergers and acquisitions, divestitures and IPOs. He has applied his voluminous knowledge of the startup landscape to help his clients in early stage financing transactions, particularly in private placements and public offerings of equity, debt and convertible securities. In this capacity, he has extensive experience advising companies in the life sciences, information technology, and clean technology industries in all aspects of corporate and securities law.